Abstract
Purpose
Sickle-cell disease-associated moyamoya syndrome (SCD-MMS) carries a high risk for recurrent strokes and cerebrovascular morbidity in children. However, few data are available about complications that occur in children hospitalized with SCD-MMS. The purpose of this analysis was to determine the risk factors for in-hospital complications in pediatric SCD-MMS admissions, and thus aid physicians in optimizing future treatment plans.
Methods
A national database of pediatric hospital admissions was examined across the years 2003–2019. ICD-9 and ICD-10 diagnosis codes were analyzed to identify discharges with a primary diagnosis of SCD-MMS and identify in-hospital complications, defined as complication-associated diagnostic codes logged during the same admission. Patient demographics, comorbidities, and hospital characteristics were examined using univariate and multivariate logistic regression analyses to determine associations with in-hospital complications.
Results
In total, 274 admissions with a primary diagnosis of SCD-MMS were identified. During 64 (23.4%) admissions, transfusion therapy was given, and in 86 admissions (31.4%), surgical revascularization was performed. In 10 admissions (3.6%), a total of 11 in-hospital complications were identified. After multivariate regression, both comorbid chronic lung disease (adjusted OR 5.3 [1.1, 26.9], P = 0.04) and surgical revascularization (adjusted OR 10.2 [2.0, 52.4], P = 0.006) were associated with development of complications.
Conclusions
In this nationwide database of pediatric SCD-MMS hospitalizations, comorbid chronic lung disease and surgical revascularization were associated with development of in-hospital complications. Patients with comorbid chronic lung disease or who are admitted for revascularization may warrant closer monitoring and greater medical optimization during the hospitalization.
Similar content being viewed by others
Data availability
Data is available through the Kids’ Inpatient Database (KID), a large pediatric inpatient database curated every 3–4 years by the Healthcare Cost and Utilization Project (HCUP) and created by the Agency for Healthcare Research and Quality. Data included in this study was aggregated from the KID across the years 2003–2019.
References
Scott RM, Smith ER (2009) Moyamoya disease and moyamoya syndrome. 360:1226–1237. https://doi.org/10.1056/NEJMRA0804622
McCrea N, Fullerton HJ, Ganesan V (2019) Genetic and environmental associations with pediatric cerebral arteriopathy. Stroke 50:257–265. https://doi.org/10.1161/STROKEAHA.118.020479
Fullerton HJ, Wintermark M, Hills NK, Dowling MM, Tan M, Rafay MF et al (2016) Risk of Recurrent arterial ischemic stroke in childhood: a prospective international study. Stroke 47:53–59. https://doi.org/10.1161/STROKEAHA.115.011173
Ghaffari-Rafi A, Ghaffari-Rafi S, Leon-Rojas J (2020) Socioeconomic and demographic disparities of moyamoya disease in the United States. Clin Neurol Neurosurg 192. https://doi.org/10.1016/J.CLINEURO.2020.105719
Kuriyama S, Kusaka Y, Fujimura M, Wakai K, Tamakoshi A, Hashimoto S et al (2008) Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke 39:42–47. https://doi.org/10.1161/STROKEAHA.107.490714
Uchino K, Johnston SC, Becker KJ, Tirschwell DL (2005) Moyamoya disease in Washington State and California. Neurology 65:956–958. https://doi.org/10.1212/01.WNL.0000176066.33797.82
Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R et al (1997) Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg 99(Suppl):2. https://doi.org/10.1016/S0303-8467(97)00031-0
Farooq S, Testai FD (2019) Neurologic complications of sickle cell disease. Curr Neurol Neurosci Rep 19:1–8. https://doi.org/10.1007/S11910-019-0932-0/TABLES/2
Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Disco D et al (2002) Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 99:3144–3150. https://doi.org/10.1182/BLOOD.V99.9.3144
Aguilar-Salinas P, Hayward K, Santos R, Agarwal V, Sauvageau E, Hanel RA et al (2019) Surgical revascularization for pediatric patients with sickle cell disease and moyamoya disease in the prevention of ischemic strokes: a single-center case series and a systematic review. World Neurosurgery 123:435-442.e8. https://doi.org/10.1016/J.WNEU.2018.11.157
DeBaun MR, Jordan LC, King AA, Schatz J, Vichinsky E, Fox CK et al (2020) American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv 4:1554–1588. https://doi.org/10.1182/bloodadvances.2019001142
Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA (2003) Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol 29:124–130. https://doi.org/10.1016/S0887-8994(03)00047-X
Newman S, Boulter JH, Malcolm JG, Pradilla I, Pradilla G (2020) Outcomes in patients with moyamoya syndrome and sickle cell disease: a systematic review. World Neurosurgery 135:165–170. https://doi.org/10.1016/J.WNEU.2019.11.137
Newman S, McMahon JT, Boulter JH, Malcolm JG, Revuelta Barbero JM, Chern JJ et al (2022) Revascularization Is associated with a reduced stroke risk in patients with sickle cell-associated moyamoya syndrome. Neurosurgery 90:441–446. https://doi.org/10.1227/NEU.0000000000001847
Jang DK, Lee KS, Rha HK, Huh PW, Yang JH, Park IS et al (2017) Bypass surgery versus medical treatment for symptomatic moyamoya disease in adults. J Neurosurg 127:492–502. https://doi.org/10.3171/2016.8.JNS152875
HCUP-US KID Overview n.d. https://hcup-us.ahrq.gov/kidoverview.jsp. Accessed Feb 22, 2024
Raygor KP, Phelps RRL, Rutledge C, Raper DMS, Molinaro A, Fox CK et al (2022) Socioeconomic factors associated with pediatric moyamoya disease hospitalizations: a nationwide cross-sectional study. J Neurosurg Pediatr 2022:1–10. https://doi.org/10.3171/2022.1.PEDS21339
Elixhauser Comorbidity Software, Version 3.7 n.d. https://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp. Accessed Oct 28, 2021
Osorio RC, Raygor KP, Abla AA (2022) Development of a customised programme to standardise comorbidity diagnosis codes in a large-scale database. BMJ Health Care Inform 29:e100532. https://doi.org/10.1136/bmjhci-2021-100532
Ravindra VM, Karsy M, Lanpher A, Bollo RJ, Griauzde J, Scott RM et al (2019) A national analysis of 9655 pediatric cerebrovascular malformations: effect of hospital volume on outcomes. J Neurosurg Pediatr 2019:1–10. https://doi.org/10.3171/2019.5.PEDS19155
Titsworth WL, Scott RM, Smith ER (2016) National analysis of 2454 pediatric moyamoya admissions and the effect of hospital volume on outcomes. Stroke 47:1303–1311. https://doi.org/10.1161/STROKEAHA.115.012168
Khoury RA, Musallam KM, Mroueh S, Abboud MR (2011) Pulmonary complications of sickle cell disease. 35:625–35. https://doi.org/10.3109/03630269.2011.621149
Siddiqui AK, Ahmed S (2003) Pulmonary manifestations of sickle cell disease. Postgrad Med J 79:384–390. https://doi.org/10.1136/PMJ.79.933.384
Miller AC, Gladwin MT (2012) Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med 185:1154–1165. https://doi.org/10.1164/rccm.201111-2082CI
Klings ES, Wyszynski DF, Nolan VG, Steinberg MH (2006) Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med 173:1264–1269. https://doi.org/10.1164/RCCM.200601-125OC
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH et al (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England J Med 330:1639–1644. https://doi.org/10.1056/NEJM199406093302303
Mutiso VM, Ongaro N (2006) Sickle cell disease in surgery. Tropical Doctor 2006:200–202
Lu Y, Lin CC, Doermann A, Patel N, Bhatia NN, Kiester PD et al (2019) Impact of sickle cell anemia on inpatient morbidity after spinal fusion. Clinical Spine Surgery 32:439–443. https://doi.org/10.1097/BSD.0000000000000819
Xu R, Xie ME, Khalifeh J, Feghali J, Yang W, Kim J et al (2022) Timing of revascularization in ischemic moyamoya disease: association of early versus delayed surgery with perioperative and long-term outcomes. World Neurosurg 166:e721–e730. https://doi.org/10.1016/j.wneu.2022.07.090
Xu R, Xie ME, Feghali J, Yang W, Kim J, Lee R et al (2022) Revascularization of hemorrhagic moyamoya disease in a North American cohort: the role of timing in perioperative and long-term outcomes. Neurosurgery 90:434–440. https://doi.org/10.1227/NEU.0000000000001850
Kokotailo RA, Hill MD (2005) Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke 36:1776–1781. https://doi.org/10.1161/01.STR.0000174293.17959.a1
Tirschwell DL, Longstreth WT (2002) Validating administrative data in stroke research. Stroke 33:2465–2470. https://doi.org/10.1161/01.str.0000032240.28636.bd
Berman MF, Stapf C, Sciacca RR, Young WL (2002) Use of ICD-9 coding for estimating the occurrence of cerebrovascular malformations. AJNR Am J Neuroradiol 23:700–705
Acknowledgements
The authors would like to acknowledge Donna M. Hays for her assistance in identifying appropriate diagnosis and procedure codes for use in this study.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by RCO, KPR and NG. The first draft of the manuscript was written by RCO and KPR, and all authors edited and commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval
This is an observational study using publicly available, anonymized data. IRB approval was not necessary for use of this de-identified dataset.
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Osorio, R.C., Raygor, K.P., Rinaldo, L. et al. Risk factors associated with in-hospital complications for pediatric sickle-cell disease-associated moyamoya syndrome: a nationwide cross-sectional study. Childs Nerv Syst (2024). https://doi.org/10.1007/s00381-024-06363-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00381-024-06363-2